Evidence map›Paper›PMID 31823319›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2020

Autologous Platelet-Rich Plasma in the Treatment of Perianal Fistula in Crohn's Disease.

F de la Portilla, A Jiménez-Salido, A Araujo-Miguez, M V Maestre-Sanchez, M L Reyes-Diaz, I Ramallo-Solís, M Ramos-Fernández, J M Vázquez-Monchul, A M García-Cabrera, R M Jimenez-Rodríguez and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

F de la PortillaColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain. delaportilla@ucpsevilla.es.ORCID http://orcid.org/0000-0003-0603-2911
A Jiménez-SalidoColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.
A Araujo-MiguezUniversity Hospital Virgen del Rocio/CSIC University of Seville, SPAIN Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain.
M V Maestre-SanchezColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.
M L Reyes-DiazColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.
I Ramallo-SolísColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.
M Ramos-FernándezColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.
J M Vázquez-MonchulColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.
A M García-CabreraColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.
R M Jimenez-RodríguezColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.
J M Díaz-PavónColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.
F J Padillo-RuizColoproctology Unit Clinical Management Unit of General and Gastrointestinal Surgery Division Seville, Biomedical Research Institute (IBIS), Avenida Manuel Siurot s/n, 41013, Seville, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess clinical healing in patients with perianal Crohn's disease with local intrafistular injection of autologous platelet-rich plasma.

methodThe pilot study was conducted at a single centre between January 2013 and December 2015. Autologous platelet-rich plasma was prepared in platelet-rich and platelet-poor fractions for local intrafistular injection in patients with proven, established perianal Crohn's disease. Patients were permitted biological therapies, and the Perianal Crohn's Disease Activity Index was recorded. Patients were followed for 48 weeks for clinical signs of healing (complete, partial or non-healing), monitoring fistula drainage, closure and epithelialization.

resultsThe study included 29 patients (19 males; mean age 38 ± 12.8 years) with four exclusions in the operating room because surgery was not indicated and four lost to follow-up. Five adverse events were recorded, with two requiring the drainage of abscess collections. Of the 21 patients assessable at 24 weeks, there was complete healing, partial healing and non-healing in 7 (33.3%), 8 (38.1%) and 6 (28.6%) patients, respectively. By 48 weeks, there was complete healing, partial healing and non-healing in 6 (40%), 6 (40%) and 3 (20%) patients, respectively, with a reduction in the number of visible external fistula openings at both time points (P = 0.021). By the end of the study, there was a higher trend of healing if biological therapies were continued (85.7% with biologics vs. 75% without, P = 0.527), but there were no statistically significant differences and no differences in the Perianal Crohn's Disease Activity Index.

conclusionAutologous platelet-rich plasma is safe in patients with perianal Crohn's disease, with an acceptable healing rate over a medium-term follow-up, particularly if biological therapies are used concomitantly.

Indexed as

Crohn DiseasePlatelet-Rich PlasmaRectal FistulaAdultHumansMaleMiddle AgedPilot ProjectsTreatment OutcomeAutologous platelet-rich plasmaFistulaPerianal Crohn’s diseaseSurgery

Identifiers

PMID31823319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.